AGN Stock Analysis: Aegon | AS
Insurance - Diversified | AS, Netherlands | Market Cap: 11.618m EUR | 12M Return: 18.2% | BMG0112X1056 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.8M
Qual. Beats: 0
Rev. Trend: -21.9%
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aegon Ltd. is a Dutch insurance and financial services company founded in 1844 and headquartered in Schiphol, the Netherlands. It provides a range of insurance and investment products-including retirement plans, mutual funds, unit-linked products, annuities, and life and health insurance-to customers across the Americas, the Netherlands, the United Kingdom, and other international markets. The company operates under well-known brands such as Transamerica and World Financial Group.
As a multi-line insurer, Aegon generates revenue from premiums across life and health policies, fees on asset management products like mutual funds, and income from unit-linked contracts, in which policyholder returns are tied to the performance of underlying investment funds. The industry is heavily regulated, and insurers typically allocate a significant portion of premiums to investment portfolios to meet long-term policy obligations.
- US interest rate cuts pressure investment portfolio returns
- Variable annuity hedging costs weigh on margins
- Transamerica segment growth drives US earnings
- Dutch pension reform shifts retirement product demand
- Capital return program funded by asset management fee income
- UK bulk annuity market competition compresses spreads
| Net Income: 1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 0.28 > 1.0 |
| NWC/Revenue: 80.06% < 20% (prev 205.4%; Δ -125.4% < -1%) |
| CFO/TA 0.00 > 3% & CFO 235.0m > Net Income 1.01b |
| Net Debt (507.0m) to EBITDA (1.12b): 0.45 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (1.57b) vs 12m ago -5.95% < -2% |
| Gross Margin: 18.83% > 18% (prev 27.53%; Δ -8.70% > 0.5%) |
| Asset Turnover: 8.05% > 50% (prev 7.39%; Δ 0.67% > 0%) |
| Interest Coverage Ratio: 4.23 > 6 (EBIT TTM 1.27b / Interest Expense TTM 300.0m) |
| A: 0.06 (Total Current Assets 20.9b - Total Current Liabilities 0.0) / Total Assets 338b |
| B: 0.01 (Retained Earnings 3.89b / Total Assets 338b) |
| C: 0.00 (EBIT TTM 1.27b / Avg Total Assets 324b) |
| D: 0.03 (Book Value of Equity 8.91b / Total Liabilities 329b) |
| Altman-Z'' = 0.50 = B |
| DSRI: 3.0 (Receivables 17.4b/3.83b, Revenue 26.1b/22.9b) |
| GMI: 1.46 (GM 27.53% / 18.83%) |
| AQI: 1.14 (AQ_t 0.94 / AQ_t-1 0.82) |
| SGI: 1.14 (Revenue 26.1b / 22.9b) |
| TATA: 0.00 (NI 1.01b - CFO 235.0m) / TA 338b) |
| Beneish M = -0.78 (Cap -4..+1) = D |
As of October 06, 2026, the stock is trading at EUR 7.62 with a total of 3,307,310 shares traded. Over the past week, the price has changed by -2.46%, over one month by -5.04%, over three months by +1.24% and over the past year by +18.22%.
Current recommended Stop Loss: 7.40 (which is 2.9% or 1.7 ATR below the current price).
Aegon has no consensus analysts rating.
P/E Trailing = 12.0769
P/E Forward = 9.2764
P/S = 0.9947
P/B = 1.2932
P/EG = 14.2828
Revenue TTM = 26.1b EUR
EBIT TTM = 1.27b EUR
EBITDA TTM = 1.12b EUR
Long Term Debt = 3.83b EUR (from longTermDebt, last quarter)
Short Term Debt = 41.0m EUR (from shortTermDebt, last fiscal year)
Debt = 4.02b EUR (from shortLongTermDebtTotal, last quarter) + Leases 187.0m
Net Debt = 507.0m EUR (calculated: Debt 4.02b - CCE 3.52b)
Enterprise Value = 12.1b EUR (11.6b + Debt 4.02b - CCE 3.52b)
Interest Coverage Ratio = 4.23 (Ebit TTM 1.27b / Interest Expense TTM 300.0m)
EV/FCF = 60.62x (Enterprise Value 12.1b / FCF TTM 200.0m)
FCF Yield = 1.65% (FCF TTM 200.0m / Enterprise Value 12.1b)
FCF Margin = 0.77% (FCF TTM 200.0m / Revenue TTM 26.1b)
Net Margin = 3.85% (Net Income TTM 1.01b / Revenue TTM 26.1b)
Gross Margin = 18.83% ((Revenue TTM 26.1b - Cost of Revenue TTM 21.2b) / Revenue TTM)
Gross Margin QoQ = 34.54% (prev none%)
Tobins Q-Ratio = 0.04 (Enterprise Value 12.1b / Total Assets 338b)
Interest Expense / Debt = 7.46% (Interest Expense 300.0m / Debt 4.02b)
Taxrate = 4.02% (39.0m / 969.0m)
NOPAT = 1.22b (EBIT 1.27b * (1 - 4.02%))
Current Ratio = unknown (Total Current Assets 20.9b / Total Current Liabilities 0.0)
Debt / Equity = 0.45 (Debt 4.02b / totalStockholderEquity, last quarter 8.91b)
Debt / EBITDA = 0.45 (Net Debt 507.0m / EBITDA 1.12b)
Debt / FCF = 2.54 (Net Debt 507.0m / FCF TTM 200.0m)
Total Stockholder Equity = 8.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.31% (Net Income 1.01b / Total Assets 338b)
RoE = 11.53% (Net Income TTM 1.01b / Total Stockholder Equity 8.72b)
RoCE = 10.10% (EBIT 1.27b / Capital Employed (Equity 8.72b + L.T.Debt 3.83b))
RoIC = 0.38% (EBIT 1.27b / (Assets 338b - Curr.Liab 0.0 - Cash 3.52b))
WACC = 8.27% (E(11.6b)/V(15.6b) * Re(8.65%) + D(4.02b)/V(15.6b) * Rd(7.46%) * (1-Tc(0.04)))
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.62 | Cagr: -9.05%
[DCF] Terminal Value 75.44% ; FCFF base≈200.0m ; Y1≈200.8m ; Y5≈212.7m
[DCF] Fair Price = 1.90 (EV 3.31b - Net Debt 507.0m = Equity 2.80b / Shares 1.47b; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -21.90 | Revenue CAGR: -4.64% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.86 | Chg30d=-2.49% | Revisions=+0% | GrowthEPS=+5.1% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=0.93 | Chg30d=+0.43% | Revisions=+17% | GrowthEPS=+7.3% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: +12% (up=3, down=2)